GSK increases supply of Menningococcal B vaccine

Recently there has been a global increase in demand for Bexsero (meningococcal B) vaccine which is reflected in Australia as well.  This means that supply to Australia isn’t meeting current demand.  We are increasing supply by five times last year’s volumes.  Anne Belcher our GM talks about the challenges in vaccine manufacture and our efforts to increase supply.